ZYNE ALERT: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Zynerba Pharmaceuticals, Inc. – ZYNE 

NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a securities class action lawsuit on behalf of shareholders who bought shares of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) between March 11, 2019 and September 17, inclusive (the Class Period).

Metadata
Provider: 
GlobeNewswire, Inc.GlobeNewswire, Inc.
Retrieved on: 
Thursday, November 21, 2019
Information
Tags: 
Civil law, Class action, Securities Class Action, NASDAQ, Finance, Economy of the United States
Geotags: 
NEW YORK, NEW YORK, Us
Organisation: 
ZHANG INVESTOR LAW P.C.
Summary
Key Points: 
  • NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a securities class action lawsuit on behalf of shareholders who bought shares of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) between March 11, 2019 and September 17, inclusive (the Class Period).
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you wish to join the case go to http://zhanginvestorlaw.com/join-action-form/?slug=zynerba-pharmaceutica... or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq.
  • or Spencer Lee toll-free at 800-991-3756 or email [email protected] , [email protected] for information on the class action.



NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a securities class action lawsuit on behalf of shareholders who bought shares of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) between March 11, 2019 and September 17, inclusive (the “Class Period”). 

If you wish to serve as lead plaintiff, you must move the Court no later than December 23, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to obtain a recovery is not dependent upon being a lead plaintiff. If you wish to join the case go to http://zhanginvestorlaw.com/join-action-form/?slug=zynerba-pharmaceuticals-inc&id=2057 or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. or Spencer Lee toll-free at 800-991-3756 or email [email protected], [email protected] for information on the class action.

如果您想加入这个集体诉讼案，请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=zynerba-pharmaceuticals-inc&id=2057.

According to the case, defendants made false and/or misleading statements and/or failed to disclose that (1) Zygel was proving unsafe and not well-tolerated in the BELIEVE 1 Trial; (2) the foregoing created a foreseeable, heightened risk that Zynerba would fail to secure the necessary regulatory approvals for commercializing Zygel for the treatment of DEE in children and adolescents; and (3) as a result, Zynerba’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class has not been certified.  You may retain counsel of your choice.  You may take no action at this time and be an absent class member. Your ability to obtain a recovery is not dependent upon being a lead plaintiff.

Zhang Investor Law represents investors worldwide.  Attorney Advertising.  Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
[email protected]
tel: (800) 991-3756

Primary Logo
Copyright: 
2019 GlobeNewswire, Inc.. All Rights Reserved.